Introduction
Elective direct current cardioversion (DCCV) remains an established treatment for Left atrial (LA) fibrosis has been associated with AF, (5) and recurrence of AF after rhythm control intervention. Clinical methods of assessment of this fibrosis include late gadolinium enhancement MRI, and invasive electrophysiological mapping. Both of these methods have been shown to have predictive value for arrhythmia recurrence after percutaneous ablation.(6,7) However, there is limited access to MRI, and EP mapping is an invasive test requiring direct access to the left atrium. Neither is therefore suitable for assessing the risk of AF recurrence after cardioversion in usual clinical practice, and more practical methods are desirable. Such a method of assessment for DCCV patients may include the use of circulating biomarkers. Studies have assessed markers of inflammation, myocardial injury, and atrial stretch with varying levels of success. (8) (9) (10) (11) (12) (13) A number of substances involved in fibrosis can be measured in peripheral blood and therefore have the potential to act as biomarkers. Evidence is conflicting regarding their use in rhythm control in general, and is sparse in the context of DCCV. (14) (15) (16) (17) (18) (19) In this study, we examined type III procollagen N terminal peptide (PIIINP) and type I collagen carboxyl telopeptide (ICTP) -two direct markers of collagen turnover. We also included galectin-3 (gal-3), a more recently identified biomarker of fibrosis that is involved with a number of steps in the inflammatory-fibrotic process, and finally fibroblast growth factor 23 (FGF-23), a hormone principally studied in the context of phosphate homeostasis, but with recent evidence suggestive of a role in AF and possibly AF-related fibrosis.
We designed a study to test the hypothesis that these four fibrosis biomarkers would predict AF recurrence after DCCV. We also hypothesised that these markers would be related to parameters of left atrial remodeling assessed by standard echocardiographic measurements, and would be higher in AF patients when compared to disease and agematched controls.
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Methods
The study was approved by the National Research Ethics Service Committee Leeds West (ref. 13 /YH/0349). All patients recruited gave written informed consent. At a single institution, patients due for DCCV for atrial fibrillation were screened between October 2014 and August 2015. Main inclusion criteria were the presence of persistent symptomatic AF requiring cardioversion and the ability to give informed consent. Main exclusion criteria were designed to avoid confounding by non-cardiac fibrotic pathology and included the presence of chronic kidney disease, malignancy, connective tissue disease or systemic inflammatory disease (e.g. interstitial lung disease or inflammatory bowel disease). Patients with a history of AF ablation were also excluded.
Participants in the control group were selected from patients attending general cardiology clinic for non-arrhythmia related conditions or symptoms. Participants were selectively recruited to create a control cohort matched for age, gender and comorbidity with the DCCV cohort. Similar exclusion criteria were applied, with the presence of any history of AF, other sustained atrial arrhythmia, or undiagnosed palpitations additionally.
External electrical cardioversions were carried out under general anaesthetic according to standard local clinical protocol. Patients were fasted for a minimum of six hours prior to induction of anaesthesia. Biphasic discharges, synchronized to the ECG R wave, were delivered up to a maximum of three times, using an escalating energy protocol of 100J, 150J, 200J. Defibrillator patches were applied to the chest wall in antero-posterior orientation. If sinus rhythm was not restored after three discharges, no further attempts at sinus rhythm restoration were made.
Blood was taken from a peripheral vein prior to cardioversion and transferred to serum separator tubes for a minimum of 30 minutes. After coagulation, the tubes were centrifuged for 15 mins at 1600g. The separated serum was then aliquoted into sterile non-pyrogenic Eppendorf tubes and frozen at -70 o C. Serum was thawed once, just prior to ELISA analysis.
Samples were analysed using commercially available enzyme-linked immunosorbent assay (ELISA) kits. Pro-collagen type III N-terminal peptide (PIIINP) and galectin-3 (Gal-3) were analysed using kits produced by Elabscience (Beijing, China). Type I collagen C-terminal telopeptide (ICTP) was analysed using kits produced by Cusabio Life Science (Wuhan, China). K serum were used to determine the appropriate dilution factor for each biomarker.
Standards of known concentration and serum samples were tested in duplicate. Serum concentrations were extrapolated from optical density readings using a 4-parameter logistic curve derived from the standards, with background correction using blank wells. Inter-and intra-assay coefficients of variation were <15%. Minimum limits of detection were; ICTP = 25 ng/mL, Gal-3 = 0.156 ng/mL, FGF-23 = 15.625 pg/mL, PIIINP = 23.438 pg/mL.
All participants underwent trans-thoracic echocardiography prior to ablation, performed by Comparison between two groups was carri S , for normal data.
Where non-parametric data could not be transformed successfully, Mann-Whitney U test was used. Univariate linear regression was used to assess the effect of baseline characteristics on biomarker levels. Variables with significant effects in univariate analysis were then examined in multivariate linear regression analysis. Univariate Cox regression analysis was used to assess predictors of arrhythmia recurrence. A two-sided p value of 0.05 was used to determine statistical significance.
To calculate power, we hypothesized that there would be an increase of 0.5 standard deviations in the levels of biomarkers in AF patients compared to controls. In order to achieve this variance using criteria of 1-.05, 35 patients per group would be required for the comparison part of the study. In order to achieve 80% statistical power to detect the difference in outcome based on biomarker levels, using p=0.05 to indicate significance, at least 20 AF recurrence events would be required. Therefore, target recruitment was set at 80 for the DCCV group and 40 for the control group.
Results
80 DCCV patients and 40 control patients were recruited. One patient was diagnosed with multiple myeloma after DCCV and died before follow up was complete T was excluded from analysis. Two further patients were lost to follow up. These patients were excluded from outcome analysis, but were included in baseline analysis. were significantly higher in the DCCV group, but there were no other differences. Biomarker levels were not significantly different between the groups, although PIIINP levels were approaching significance for being higher in AF patients (p = 0.068). There were no significant differences between distribution of biomarker levels in patients with AF recurrence and those without.
In univariate Cox regression analysis of all baseline characteristics (table 3) , only FGF-23 was found to be weakly associated with arrhythmia recurrence (HR 1.003, p=0.012). The hallmark of fibrosis is an increase in volume and turnover of extracellular matrix (ECM).
In the heart, ECM is comprised predominantly of type I, and to a lesser extent type III, 
DCCV patients vs controls
This study is, to our knowledge, unique in comparing AF patients selected for DCCV to age and disease-matched controls when assessing biomarkers of fibrosis. In this study, there was no difference between levels of the four biomarkers between the DCCV patients and controls, which were well-matched for age and comorbidities. PIIINP levels approached significance for being higher in AF patients, suggesting that either there is no true difference, or perhaps that any true difference is so slight as to be undetectable in a study of this size. Overall these findings are suggestive that either the DCCV patients had similar levels of fibrosis to the controls, or any differences in fibrosis were not detectable using these biomarkers peripherally. This may be accounted for by the fact that the controls were not disease-free, and comorbidity in the control group may have accounted for a rise in biomarker levels, therefore masking any specific contribution of AF to biomarker levels in the DCCV cohort. It may be the comorbidities present in AF patients that cause the increase in fibrosis biomarkers noted in other studies. It should be noted that one of the limitations of this study is the impossibility of excluding non-symptomatic paroxysmal AF in the control group, however it is unlikely that this would have been a significant problem. involves heterogenous patient groups between studies and it can therefore be difficult to draw firm conclusions regarding the overall AF patient population. In our study, only left atrial dimensions were different between the groups. As left atrial remodeling is a known effect of AF, this is to be expected. As the controls appear to be more well-matched than in other studies, the results are more robust.
Predictive value of the biomarkers PIIINP, ICTP and Gal-3 had no predictive value for recurrence of AF. FGF-23, however, was found to be significantly, but weakly associated with recurrence, with a hazard ratio of 1.003 per 1 pg/mL increase in FGF-23 level. This result has not previously been reported, but must be interpreted with caution due to the low number of valid results for this biomarker compared to the overall number of patients, due to the limitations of the ELISA assay. It is possible that a more sensitive test may be able to explore this finding further.
Gal-3 has not been studied in the context of DCCV, however in ablation results have been in their study were similar to ours, with the notable exceptions of LV ejection fraction, which was lower in our cohort, and duration of AF which was much higher in our cohort. This may explain why this study did not reproduce their results, and we feel that our cohort more DCCV .
Finally Kallergis et. al. showed an association between recurrence and ICTP in their study of 164 DCCV patients. Notably however, they excluded patients with a significant number of comorbidities which may make their findings difficult to generalize to the AF population.
Conclusion
PIIINP, ICTP, and Gal-3 are not predictive of AF recurrence after DCCV. FGF-23 may be associated with arrhythmia recurrence, but further work is required to clarify this. The presence of AF has no effect on levels of these biomarkers when compared to age and disease-matched controls.
